A 51-year-old woman presents to the PMHNP with complaints of depressed mood, fatigue, and anhedonia. She is in menopause and reports vasomotor symptoms. Which of the following medications effectively treats both depressive and vasomotor symptoms?

Choice A reason: Bupropion primarily acts as a norepinephrine-dopamine reuptake inhibitor and is effective in treating depressive symptoms. However, it has little to no efficacy in managing vasomotor symptoms associated with menopause, such as hot flashes or night sweats, and therefore would not address both conditions simultaneously. Choice B reason: Escitalopram, a selective serotonin reuptake inhibitor, is effective in treating depression and anxiety but has limited effectiveness in alleviating vasomotor symptoms. While SSRIs can sometimes help with hot flashes, their efficacy is not as pronounced as that of certain SNRIs like desvenlafaxine. Choice C reason: Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, has demonstrated efficacy in treating both depressive symptoms and vasomotor symptoms such as hot flashes in menopausal women. Its dual action on serotonin and norepinephrine pathways contributes to both mood stabilization and modulation of thermoregulatory symptoms, making it the optimal choice for patients presenting with both conditions. Choice D reason: Duloxetine is also an SNRI effective for depression and anxiety. While it can have some effect on vasomotor symptoms, its evidence base for treating menopausal hot flashes is less robust compared to desvenlafaxine. Therefore, it is not the first-line option when targeting both depression and vasomotor symptoms simultaneously.